Cargando…

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Detalles Bibliográficos
Autores principales:	Iacoboni, Gloria, Rejeski, Kai, Villacampa, Guillermo, van Doesum, Jaap A., Chiappella, Annalisa, Bonifazi, Francesca, Lopez-Corral, Lucia, van Aalderen, Michiel, Kwon, Mi, Martínez-Cibrian, Nuria, Bramanti, Stefania, Reguera-Ortega, Juan Luis, Camacho-Arteaga, Lina, Schmidt, Christian, Marín-Niebla, Ana, Kersten, Marie José, Martin Garcia-Sancho, Alejandro, Zinzani, Pier Luigi, Corradini, Paolo, van Meerten, Tom, Subklewe, Marion, Barba, Pere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631549/ https://www.ncbi.nlm.nih.gov/pubmed/35271707 http://dx.doi.org/10.1182/bloodadvances.2021006922

Ejemplares similares

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
por: Ahmed, Nausheen, et al.
Publicado: (2023)

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)
por: Locke, F., et al.
Publicado: (2022)

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
por: Ball, Graeme, et al.
Publicado: (2022)

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
por: Shah, Bijal D, et al.
Publicado: (2023)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
por: Marchetti, Monia
Publicado: (2023)

Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
por: Dean, Erin A., et al.
Publicado: (2023)

P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
por: Shah, Bijal, et al.
Publicado: (2023)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

High frequency of hyperglycaemia observed during CAR T‐cell treatment
por: Tienstra, Marieke, et al.
Publicado: (2022)

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
por: Morello, Lucia, et al.
Publicado: (2019)

Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands
por: van Doesum, Jaap, et al.
Publicado: (2020)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
por: van Doesum, Jaap A., et al.
Publicado: (2021)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
por: Delforge, Michel, et al.
Publicado: (2022)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

Semi-automated (18)F-FDG PET segmentation methods for tumor volume determination in Non-Hodgkin lymphoma patients: a literature review, implementation and multi-threshold evaluation
por: Keijzer, Kylie, et al.
Publicado: (2023)

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
por: Tilch, Marie-Kristin, et al.
Publicado: (2022)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
por: Abrisqueta, Pau, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy
por: Marangon, Miriam, et al.
Publicado: (2021)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
por: Serna, Angel, et al.
Publicado: (2022)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

Childhood Asthma: Diagnosis and Treatment
por: van Aalderen, Wim M.
Publicado: (2012)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Coexisting Mantle Cell Lymphoma and Prostate Adenocarcinoma
por: Rajput, Ashish B., et al.
Publicado: (2014)

P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Garcia-Calvo, Gloria Ines Iacoboni, et al.
Publicado: (2023)

Strong plates enhance mantle mixing in early Earth
por: Agrusta, Roberto, et al.
Publicado: (2018)

Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma
por: Maas, Dominique, et al.
Publicado: (2018)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fr8b06fr6iinvqcnh0qemt1jjm